We are live on ! Find out more

Mid Cap
Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
ALKS icon
1
Alkermes
ALKS
$7.55B
$7.55B $44.94 2.69%
KNSA icon
2
Kiniksa Pharmaceuticals
KNSA
$7.38B
$7.38B $93.89 0.37%
AMRX icon
3
Amneal Pharmaceuticals
AMRX
$7.36B
$7.36B $21.12 1.26%
LNTH icon
4
Lantheus
LNTH
$6.68B
$6.68B $102.10 0%
SUPN icon
5
Supernus
SUPN
$5.94B
$5.94B $28.61 0.92%
LQDA icon
6
Liquidia
LQDA
$4.9B
$4.9B $54.43 3.88%
HIMS icon
7
Hims & Hers Health
HIMS
$3.42B
$3.42B $14.60 8.86%
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$3.35B
$3.35B $26.02 0.69%
XERS icon
9
Xeris Biopharma Holdings
XERS
$3.1B
$3.1B $16.97 2.11%
BHC icon
10
Bausch Health
BHC
$3.08B
$3.08B $8.22 3.97%
PBH icon
11
Prestige Consumer Healthcare
PBH
$2.35B
$2.35B $49.63 0.06%
HCM icon
12
HUTCHMED
HCM
$2.3B
$2.3B $13.22 1.71%
PRGO icon
13
Perrigo
PRGO
$2.21B
$2.21B $15.94 0.62%
RGC icon
14
Regencell Bioscience
RGC
$2.07B
$2.07B $4.18 4.13%

Mid Cap Drug Manufacturers - Specialty & Generic Stocks at a Glance

Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.

There are 14 mid cap Drug Manufacturers - Specialty & Generic stocks — companies in the Drug Manufacturers - Specialty & Generic industry with a market cap between $2B and $10B — worth a combined $61.7B.

The largest by market cap are Alkermes (ALKS) at $7.55B, Kiniksa Pharmaceuticals (KNSA) at $7.38B and Amneal Pharmaceuticals (AMRX) at $7.36B.

Among institutional investors, Kiniksa Pharmaceuticals (KNSA) drew the most net new fund positions in Q3 2026: 71 funds opened new positions, taking total fund holders up 40 (15%) quarter-over-quarter.

  • Combined market cap: $61.7B across 14 stocks.
  • Mid Cap: market cap between $2B and $10B.
  • Largest constituent: Alkermes (ALKS), $7.55B market cap.
  • Most net new fund positions in Q3 2026: Kiniksa Pharmaceuticals (KNSA), +40 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.